Analysis
Aspen Neuroscience priced its initial public offering of 9,375,000 shares at $15.00 per share for expected gross proceeds of approximately $140.6 million, with trading set to begin on the Nasdaq Global Select Market under the ticker ASPE on October 30, 2026. Pulse previously covered Aspen's plan to go public after raising roughly $340 million-plus privately; this pricing is the event that follows through on that filing.
What Aspen Neuroscience does
Aspen is a clinical-stage biotechnology company headquartered in San Diego, founded in 2018 with $6.5 million in seed funding. Its lead program, ANPD001, is a single-dose, autologous dopaminergic neuron precursor cell therapy for moderate to advanced Parkinson's disease -- autologous meaning the cells are derived from the patient's own tissue rather than a universal donor line. The company has also received an $8 million grant from the California Institute for Regenerative Medicine to support its work.
Aspen's funding history, before the IPO
Aspen's pre-IPO rounds:
“Aspen is a clinical-stage biotechnology company headquartered in San Diego, founded in 2018 with $6.5 million in seed funding.”
- Series A, early 2020 -- $70M.
- Series B, May 2022 -- roughly $147.5M, co-led by GV, LYFE Capital and Revelation Partners, with new investors Newton Investment Management, Singapore's EDBI and LifeForce Capital.
- Series C, November 2025 -- $115M, co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences and Revelation Partners.
That brought Aspen's total capital raised to more than $340 million heading into this IPO. That private total -- larger than the $140.6 million this IPO itself raises -- is a reminder that a public debut doesn't always represent a company's biggest capital event; for many biotechs, the IPO is about establishing a public currency and liquidity path more than raising the single largest check.
Who invested in Aspen, and who's underwriting the IPO
The November 2025 Series C brought in new investors including Kite (a Gilead Company), Balyasny Asset Management and Cormorant Asset Management, alongside existing backers Medical Excellence Capital, S32, Axon Ventures and LYFE Capital. Earlier Series A and seed investors included OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture Investments. For the IPO itself, Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer & Co. are acting as joint bookrunning managers.
Cell therapy market and competitors
Aspen's autologous approach to Parkinson's cell therapy puts it in a field that includes BlueRock Therapeutics, the Bayer-owned company advancing its own cell therapy, bemdaneprocel, into registrational Phase III trials for Parkinson's -- a allogeneic, off-the-shelf approach rather than Aspen's patient-derived model. The two approaches represent competing bets on whether personalized or universal donor cells will ultimately win out on cost, manufacturing speed and clinical efficacy in treating the disease.
What to watch next
The near-term question is how ASPE trades on its Nasdaq debut and whether investors reward Aspen's personalized-cell approach with a premium over BlueRock's allogeneic model, or discount it for the manufacturing complexity that comes with patient-specific therapies. Aspen's ANPD001 program's next clinical readouts will matter far more than the IPO pricing itself for the stock's medium-term direction.
The risk, as with any clinical-stage biotech IPO, is that Aspen has not disclosed data showing ANPD001 works in a registrational-size trial; the $140.6 million raised here is runway to get more data, not confirmation the therapy succeeds.